PMDAapproval72% confidence
[SHINSA]English Translation of Review Report: Blenrep, Neffy, and Tecentriq (Partial Change Approval)
Source: PMDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (cardiology) as AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class T.
Regulatory Analysis
PMDA document relevant to the signal.
Supporting Context
- Therapeutic area
- Cardiology · Hypertension
- Sub-indication
- Hypertension
Related signal: AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment